Description: Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.
Home Page: www.protalix.com
Science Park
Karmiel,
2161401
Israel
Phone:
972 4 902 8100
Officers
| Name | Title |
|---|---|
| Mr. Dror Bashan | President, CEO & Director |
| Mr. Eyal Rubin M.B.A. | Senior VP, CFO, Treasurer & Corporate Secretary |
| Mr. Yaron Naos | Senior Vice President of Operations |
| Ms. Yael Fellous | Vice President of Human Resources |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 2.6323 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.7642 |
| Price-to-Sales TTM: | 3.0312 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 208 |